GlassScriptPhysician profile
James R Stewart
NPI 1689758294
$8,874.23
in general payments reported to CMS, 2019-2025
52 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $699 · 2021: $1,212 · 2022: $1,626 · 2023: $1,905 · 2024: $1,151 · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,706.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $932.29 | 2019-2025 | Vraylar |
| Glaxosmithkline, LLC. | $927.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $780.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $668.88 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $532.97 | 2022-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Novo Nordisk INC | $327.53 | 2019-2025 | Ozempic, Wegovy |
| Mannkind Corporation | $317.90 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $294.79 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Sunovion Pharmaceuticals INC. | $292.97 | 2019-2022 | |
| Almatica Pharma LLC | $286.35 | 2021-2024 | Loreev Xr, Gralise, Teriparatide |
| Nestle Healthcare Nutrition INC. | $226.95 | 2021-2023 | |
| Allergan, INC. | $224.09 | 2020 | |
| Amgen INC. | $208.29 | 2019-2025 | Evenity, Krystexxa |
| Sumitomo Pharma America, INC. | $190.74 | 2023-2025 | Gemtesa, Aptiom |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.55 | 2024-2025 | Caplyta |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.